| 标题 |
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2) |
| 网址 | |
| DOI | |
| 其它 |
期刊:Journal of the American Academy of Dermatology 作者:Mark G. Lebwohl; Craig L. Leonardi; Nehal N. Mehta; Alice B. Gottlieb; Alan M. Mendelsohn; et al 出版日期:2021 |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)